Please ensure JavaScript is enabled for purposes of website accessibility Neuromyelitis Optica Spectrum Disorder Symptoms | For HCPs

You are now leaving nmosdsymptoms.com

Horizon is not responsible for the content of external websites linked within nmosdsymptoms.com. Do you want to continue? .

Yes No

Is it time to act? Your NMOSD patients may be revealing new or worsening disease activity like pain, vision changes, or bladder/bowel symptoms or have difficulty with dosing regimens.1,2

If you hear these cries for help, it may be time to intervene.

NMOSD management should include:

early-accurate-diagnosis-icon

Evaluating the long-term efficacy of therapy2

Methods of Monitoring
patient-quality-of-life-icon

Assessing the ongoing impact of the disease1,2             

See How Disability Can Accumulate
No-FDA-approved-therapies

Treatment decisions that involve more than attack reduction alone3,4

Explore the Evolution of Treatment

Support

Explore NMOSD resources

Support for Your Patients

Stay Up to Date

Receive the latest information about NMOSD

Sign Up Now

NMOSD, neuromyelitis optica spectrum disorder.

  • References

    1. Eaneff S, Wang V, Hanger M, et al. Patient perspectives on neuromyelitis optica spectrum disorders: data from the PatientsLikeMe online community. Mult Scler Relat Disord. 2017;17:116-122.
    2. Paul F, Marignier R, Palace J, et al. International Delphi Consensus on the management of AQP4· lgG+ NMOSD: recommendations for eculizumab, inebilizumab, and satralizumab. Neurol Neuroimmunol Neuroinflamm. 2023;10(4):e200124. doi: 10.1212/NXl.0000000000200124
    3. Held F, Klein A-K, Berthele A. Drug treatment of neuromyelitis optica spectrum disorders: out with the old, in with the new? Immunotargets Ther. 2021;10:87-101
    4. Wingerchuk DM, Lucchinetti CF. Neuromyelitis optica spectrum disorder. N Engl J Med. 2022;387:631-639. doi:10.1056/NEJMra1904655